INTRODUCTION
Ankylosing spondylitis (AS) is a chronic rheumatic disease that affects the spine and sacroiliac joints, causing pain and inflammation. The global prevalence is between 0.1% and 1.4%, and patients with active disease may present diminished physical functioning due the loss of lumbar mobility. As such, AS can also affect patient quality of life and participation in paid and unpaid work. It can also be an important component of healthcare costs [1, 2] . The estimated annual indirect costs of AS were reported to range from €3188 to €8862 per patient in the Netherlands, France and Belgium, while the mean direct costs were €2640 per patient/year, with 13% of the costs related to drug expenditure [3] . In Brazil, the estimated direct cost of AS treatment was US$21,091 per patient/year in 2011 for outpatients of a rheumatology service.
Medications accounted for 96% of the cost, and 63% of patients were using the tumour necrosis factor blockers (anti-TNF) infliximab, etanercept or adalimumab [4] . The anti-TNF drugs are second-line treatment for AS and are used in patients whose disease activity remains high despite the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Other AS therapies include disease-modifying antirheumatic drugs (DMARDs), such as sulfasalazine and methotrexate, for patients with peripheral arthritis [5, 6] . Following the introduction and wide-spread use of anti-TNF agents in clinical practice, the drug costs have increased and become the most important driver of direct costs in the management of AS [7] . In Brazil, patients with a diagnosis of AS have access to free-of-charge medical care and drug therapy through the Brazilian Public Health System (SUS We performed a cost analysis from the health system perspective and included the 
DISCUSSION
In this study we evaluated 1251 patients with AS who had received treatment in Minas Gerais through the SUS during the period 2010-2013.
We observed a gender and age distribution similar as to that described in the literature [1] . Most patients included in the study cohort had initiated AS treatment with adalimumab or etanercept, which were the most frequently dispensed drugs during the study period. Few patients had been dispensed DMARDs, which are primarily indicated for peripheral arthritis that affects about 20% of AS patients [1, 2] .
The mean monthly cost for AS drug therapy increased from 2010 to 2013 due to an increase in both the number of patients with AS who were treated and the frequency of dispensation of anti-TNF agents. The estimated annual drug cost was US$ 10 million in 2013, which [10] . To the contrary, an Austrian study reported no significant difference among the three TNF blockers, and the monthly cost for drugs per patient was US $1142 in 2007 (anti-TNF drugs accounted for 95% of that amount) [11] . In 2010, the National Health Service (NHS) in the UK withdrew infliximab from the list of recommended drugs for AS treatment following new evidence of reduced cost-effectiveness compared to etanercept and adalimumab [12] .
In comparison to DMARDs the anti-TNF drugs are very expensive, but the costs of treatment can be balanced with potential long-term cost savings. Since AS is highly prevalent among patients in the most productive age ranges, indirect costs are an important driver of total costs on AS therapy [4, 7] . Treated patients can expect an improved quality of life and a cessation/modulation of disease progression, potentially decreasing both the direct costs of the disease, including use of other medications and health services, and indirect costs associated with disability, early retirement and sick leave [3, 4, 13] . In Brazil, the annual per capita indirect costs due to AS have been reported to be US$ 3623 in terms of retirement and US$ 2451 in terms of sick leave [4] . Nevertheless, another Brazilian study focusing on patients with rheumatic diseases reported that after 6 months of treatment with biological drugs, the quality of life improved in the sample as a whole and in participants with AS. In addition, those participants with the poorest functionality at baseline exhibited a greater improvement in quality of life relative to those participants with a better functional status at baseline [14] .
Given the relative lack of head-to-head studies among anti-TNF agents, there is to date no consensus on which drug has the highest efficacy in terms of AS treatment. [16] [17] [18] [19] [20] . Based on these results, both Brazilian and international recommendations do not indicate a preference for any one of the drugs available for the treatment of axial disease manifestations [5, 6] . However, drug cost should be one criterion for the choice of appropriate therapy, 
